

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition that is useful as a medicine for the treatment of hypopytialism, characterized in that it comprisescomprising pilocarpine combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity.

2. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition that is useful as a medicine for the treatment of hypopytialism according to claim 1, wherein the pilocarpine is the basic pilocarpine or pilocarpine in the form of salt, chlorohydrate or nitrate.

3. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition that is useful as a medicine for the treatment of hypopytialism according to claim 1, wherein it the composition is further combined with a mass substrate of the family of soluble carbohydrates with a low molecular weight, glucose or lactose.

4. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition that is useful as a medicine for the treatment of hypopytialism according to claim 1, wherein it comprises at leastfurther comprising a buffer.

5. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further comprising at least one lubricant.

6. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further comprising at least one softening agent.

7. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further comprising at least one hydrophilic substance.

8. (Currently Amended) Galenical A galenical formulation that includes a comprising the composition according to claim 1, wherein it makes it possible with the pilocarpine: the formulation:

[[-]] makes it possible for the pilocarpine to directly and instantaneously access the muscarine-like receptors of the submucous glandular structures;[[],]

[[-]] to protect it and protects the pilocarpine to keep it stable with regard to the light, the temperature and the oxidation;[[],] and

[[-]] to allow it allows the pilocarpine to dissolve and to be attached locally to tissues of the buccopharyngeal cavity.

9. (Currently Amended) Sublingual A sublingual tablet for the treatment of hypothyroidism, having comprising the pharmaceutical composition according to claim 1, wherein it comprises at least the pilocarpine and at least one bioadhesive polymer.

10. (Currently Amended) Sublingual The sublingual tablet for the treatment of hypothyroidism according to claim 9, wherein the bioadhesive polymer is selected from among the family of the group consisting of: cellulose derivatives, gums or polymers of the alginic acid type and derivatives, carboxy-vinyl polymer, carbomer, macrogols, gelatin, povidone, or and pectins.

11. (Currently Amended) Sublingual The sublingual tablet for the treatment of hypothyroidism according to claim 9, wherein it has the following formula the tablet comprises:

[[-]] 2.5 mg pilocarpine that is basic or in salt form, [:] 2.5 mg

[[-]] 10.0 mg magnesium stearate, [:]

10.0 mg

[[-]] 90.0 mg sodium or disodium hydrogen phosphate, [:] 90.0 mg

[[-]] 50.0 mg K 100 methocel, [:]

50.0 mg

[[-]] 6-000-40.0 mg polyethylene glycol, 6000[[:]]

40.0 mg

[[-]] 20.0 mg hyaluronic acid, [[:]]

20.0 mg

[[-]] 15.0 mg lysozyme chlorohydrate, and[[:]]

15.0 mg

[[-]] 772.5 mg compressed sorbitol qsp for 1000
mg. [[:]] 772.5 mg

12. (Currently Amended) ~~Sublingual~~ The sublingual tablet
~~for the treatment of hypoptyalism~~ according to claim 11, wherein
the sodium or disodium hydrogen phosphate is replaced by sodium
carbonate or sodium bicarbonate in the same proportions.

13. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical
composition ~~that is useful as a medicine for the treatment of~~
~~hypoptyalism~~ according to claim 2, ~~wherein it comprises at least~~
further comprising a buffer.

14. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical
composition ~~that is useful as a medicine for the treatment of~~
~~hypoptyalism~~ according to claim 3, ~~wherein it comprises at~~
~~least~~further comprising a buffer.

15. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical
composition ~~that is useful as a medicine for the treatment of~~
~~hypoptyalism~~ according to claim 2, ~~wherein it comprises~~further
comprising at least one lubricant.

16. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 3, wherein it comprisesfurther comprising at least one lubricant.

17. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 2, wherein it comprisesfurther comprising at least one softening agent.

18. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 3, wherein it comprisesfurther comprising at least one softening agent.

19. (Currently Amended) Pharmaceutical The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 2, wherein it comprisesfurther comprising at least one hydrophilic substance.

20. (Currently Amended) Sublingual The sublingual tablet for the treatment of hypoptyalism according to claim 10, wherein it has the following formula the tablet comprises:

[[-]] 2.5 mg pilocarpine that is basic or in salt form, [[:]]
[[:]]

[[-]] 10.0 mg magnesium stearate, [[:]]

10.0 mg

[[-]] 90.0 mg sodium or disodium hydrogen phosphate, [[:]] 90.0 mg
[[-]] 50.0 mg K 100 methocel, [[:]]
50.0 mg
[[-]] 40.0 mg 6-000 polyethylene glycol 6000, [[:]]
40.0 mg
[[-]] 20.0 mg hyaluronic acid, [[:]]
20.0 mg
[[-]] 15.0 mg lysozyme chlorohydrate, and [[:]]
15.0 mg
[[-]] 772.5 mg compressed sorbitol qsp for 1000
mg, [[:]] 772.5 mg